Avadel Pharmaceuticals Q1 2024 Earnings Report $8.41 -0.06 (-0.71%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Avadel Pharmaceuticals EPS ResultsActual EPS-$0.30Consensus EPS -$0.25Beat/MissMissed by -$0.05One Year Ago EPS-$0.48Avadel Pharmaceuticals Revenue ResultsActual Revenue$27.18 millionExpected Revenue$25.89 millionBeat/MissBeat by +$1.29 millionYoY Revenue Growth+2,617.80%Avadel Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/8/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSEC FilingAVDL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Avadel Pharmaceuticals Earnings HeadlinesAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 20 at 4:05 PM | globenewswire.comDeutsche Bank Aktiengesellschaft Begins Coverage on Avadel Pharmaceuticals (NASDAQ:AVDL)February 13, 2025 | americanbankingnews.comCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.February 22, 2025 | Behind the Markets (Ad)Head to Head Contrast: BioMarin Pharmaceutical (NASDAQ:BMRN) & Avadel Pharmaceuticals (NASDAQ:AVDL)February 13, 2025 | americanbankingnews.comDeutsche Bank Initiates Coverage of Avadel Pharmaceuticals (AVDL) with Buy RecommendationFebruary 12, 2025 | msn.comAvadel Pharmaceuticals: Moving To A Speculative BuyFebruary 11, 2025 | seekingalpha.comSee More Avadel Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avadel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avadel Pharmaceuticals and other key companies, straight to your email. Email Address About Avadel PharmaceuticalsAvadel Pharmaceuticals (NASDAQ:AVDL) operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.View Avadel Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
